Full text is available at the source.
Abstract
No nationally representative cohort has characterized real-world uptake of GLP-1/GIP therapies.
- Evidence on GLP-1/GIP therapies may not reflect broader patient experiences due to reliance on selected populations.
- Utilization patterns outside healthcare channels are not well documented in existing studies.
- The current understanding of indications and access to these therapies may be limited by the study populations involved.
Simplified